Eisai Inc.
Eisai Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States and operates extensively across North America and beyond. Founded in 1941, Eisai has established itself as a leader in the development of innovative treatments, particularly in neurology and oncology. The company is renowned for its core products, including the Alzheimer's treatment Aricept and the anti-cancer agent Lenvima, both of which exemplify Eisai's commitment to addressing unmet medical needs. With a strong focus on research and development, Eisai has achieved significant milestones, including numerous FDA approvals and partnerships that enhance its market position. The company's dedication to patient-centric solutions and its unique approach to drug development underscore its reputation as a trusted name in healthcare, making Eisai Inc. a vital contributor to advancements in medical science.
DitchCarbon Score
How does Eisai Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eisai Inc.'s score of 41 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Eisai Inc.'s reported carbon emissions
In 2020, Eisai Inc. reported its carbon emissions data, although specific absolute emissions figures in kg CO2e were not disclosed. The company has not provided detailed information regarding its Scope 1, 2, or 3 emissions, nor has it set specific reduction targets or initiatives as part of its climate commitments. Eisai's emissions data from previous years indicates a trend in CO2 emissions per million yen, with values of approximately 0.0000798 in 2017, 0.0000746 in 2016, 0.0000704 in 2018, 0.0000656 in 2019, and 0.0000753 in 2020. However, without concrete total emissions figures, it is challenging to assess the overall impact or progress towards climate goals. Currently, Eisai does not appear to have established any formal reduction targets or commitments to the Science Based Targets initiative (SBTi), which is a common framework for companies aiming to align their emissions reductions with climate science. As such, the company's climate strategy remains somewhat unclear within the context of industry standards.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eisai Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
